We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · October 03, 2022

First-Line Pembrolizumab vs Dabrafenib/Trametinib for BRAF V600–Mutant Melanoma

Journal of the American Academy of Dermatology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Journal of the American Academy of Dermatology
First-line pembrolizumab versus dabrafenib/trametinib treatment for BRAF V600-mutant advanced melanoma
J Am Acad Dermatol 2022 Sep 03;[EPub Ahead of Print], CG Kim, M Kim, J Hwang, ST Kim, M Jung, KH Kim, KH Kim, JS Chang, WS Koom, MR Roh, KY Chung, TM Kim, SK Kim, J Lee, SJ Shin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading